Chronic kidney disease (CKD) is defined by reduced GFR and/or kidney damage persisting beyond three months. Reflux nephropathy — CKD from vesicoureteral reflux and progressive scarring — shares most management principles with general CKD, and both now benefit from a rapidly expanding set of kidney-protective therapies.
The pillars of kidney protection
Modern CKD care is organized around several complementary, evidence-based therapies. RAAS blockade (ACE inhibitors or ARBs) remains foundational for proteinuric CKD. SGLT2 inhibitors now slow progression and reduce cardiovascular and mortality risk across CKD — diabetic and non-diabetic alike — and are recommended add-ons in the 2024 KDIGO CKD guideline. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, adds further reduction of albuminuria and progression with a lower hyperkalemia risk than older agents, and GLP-1 receptor agonists (notably semaglutide) reduce kidney and cardiovascular events in CKD with type 2 diabetes. Combining these mechanisms — rather than adding them sequentially — is the current direction of travel.
Emerging agents
Several newer classes are advancing: aldosterone synthase inhibitors (to reduce aldosterone-driven injury with less hyperkalemia), endothelin receptor antagonists (atrasentan, zibotentan) for proteinuric CKD, and soluble guanylate cyclase agonists to improve renal blood flow and reduce albuminuria.
Reflux nephropathy specifics
Management centers on preventing recurrent urinary tract infection, surgical correction of severe vesicoureteral reflux where indicated, and tight control of blood pressure and proteinuria, with close surveillance for progressive scarring. Alongside, the usual CKD complications — anemia, metabolic acidosis, and mineral-bone disorder — are managed on their own tracks, with statins and lifestyle measures for cardiovascular risk.
| Therapy | Role | Note |
|---|---|---|
| ACEi/ARB | All proteinuric CKD | Foundational |
| SGLT2 inhibitors | All CKD | Slows progression; CV/mortality benefit |
| Finerenone | Add-on | Extra albuminuria reduction; monitor potassium |
| GLP-1 agonists | CKD + type 2 diabetes | Kidney and CV benefit |
| Aldosterone synthase inhibitors, ERAs, sGC agonists | Emerging | In trials |
Further reading: 2024 KDIGO CKD evaluation-and-management guideline; SGLT2-inhibitor CKD trials (DAPA-CKD, EMPA-KIDNEY); FIDELIO/FIDELITY finerenone; FLOW semaglutide.